BR0311360A - métodos para expansão e transdiferenciação in vitro de células acinares pancreáticas humanas em células produtoras de insulina - Google Patents

métodos para expansão e transdiferenciação in vitro de células acinares pancreáticas humanas em células produtoras de insulina

Info

Publication number
BR0311360A
BR0311360A BR0311360A BR0311360A BR0311360A BR 0311360 A BR0311360 A BR 0311360A BR 0311360 A BR0311360 A BR 0311360A BR 0311360 A BR0311360 A BR 0311360A BR 0311360 A BR0311360 A BR 0311360A
Authority
BR
Brazil
Prior art keywords
cells
methods
insulin producing
transdifferentiation
human pancreatic
Prior art date
Application number
BR0311360A
Other languages
English (en)
Inventor
Sharon C Presnell
Neil Robbins
Mohammad Heidaran
Perry Haaland
Paul P Latta
David W Scharp
Margaret Coutts
Catherine Micintyre
Original Assignee
Becton Dickinson Co
Novocell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co, Novocell Inc filed Critical Becton Dickinson Co
Publication of BR0311360A publication Critical patent/BR0311360A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/315—Prolactin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/335—Glucagon; Glucagon-like peptide [GLP]; Exendin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/34—Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/345—Gastrin; Cholecystokinins [CCK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/35—Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/37—Parathyroid hormone [PTH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/80—Neurotransmitters; Neurohormones
    • C12N2501/83—Tachykinins, e.g. substance P
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/85—Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"MéTODOS PARA EXPANSãO E TRANSDIFERENCIAçãO IN VITRO DE CéLULAS ACINARES PANCREáTICAS HUMANAS EM CéLULAS PRODUTORAS DE INSULINA". Esta invenção diz respeito, por exemplo, a um método para expandir células acinares de mamífero, que compreende cultivar as células em um sistema de cultura de células que compreende um meio de cultura de células e uma superfície de anexação das células, sob condições em que as células acinares são submetidas a uma expansão de 3-4 vezes juntamente com transdiferenciação em um fenótipo de célula modificada (células IP) que apresenta características de células acinares e células hepáticas. A invenção também diz respeito a um método para transformar essas células IP em células produtoras de insulina in vitro, que compreende cultivar as células em um meio inédito definido. São também revelados meios de cultura adequados para realizar esses métodos, células isoladas que têm o fenótipo de células IP e/ou produzidas por esses métodos, e estojos para realizar os métodos.
BR0311360A 2002-05-28 2003-05-22 métodos para expansão e transdiferenciação in vitro de células acinares pancreáticas humanas em células produtoras de insulina BR0311360A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38400002P 2002-05-28 2002-05-28
PCT/US2003/016124 WO2003102134A2 (en) 2002-05-28 2003-05-22 Pancreatic acinar cells into insulin producing cells

Publications (1)

Publication Number Publication Date
BR0311360A true BR0311360A (pt) 2006-06-06

Family

ID=29584613

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0311413A BR0311413A (pt) 2002-05-28 2003-05-22 Desenvolvimento e transdiferenciação de células acinares humanas
BR0311360A BR0311360A (pt) 2002-05-28 2003-05-22 métodos para expansão e transdiferenciação in vitro de células acinares pancreáticas humanas em células produtoras de insulina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0311413A BR0311413A (pt) 2002-05-28 2003-05-22 Desenvolvimento e transdiferenciação de células acinares humanas

Country Status (8)

Country Link
US (5) US20060122104A1 (pt)
EP (3) EP1578925A4 (pt)
JP (2) JP2006512046A (pt)
CN (2) CN1662643A (pt)
AU (3) AU2003273573A1 (pt)
BR (2) BR0311413A (pt)
CA (2) CA2487094A1 (pt)
WO (3) WO2003102134A2 (pt)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101089591B1 (ko) * 2001-12-07 2011-12-05 제론 코포레이션 인간 배아 줄기세포 유래의 섬세포
US20060122104A1 (en) * 2002-05-28 2006-06-08 Presnell Sharon C Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
ATE437941T1 (de) * 2003-06-20 2009-08-15 Vrije Universiteit Brussel Vub Verfahren zur erzeugung von beta-inselzellen aus exokrinen pankreaszellen
ES2597837T3 (es) 2003-06-27 2017-01-23 DePuy Synthes Products, Inc. Células posparto derivadas de tejido de la placenta, y métodos de fabricación y utilización de los mismos
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
AU2004260815B2 (en) * 2003-07-28 2010-05-20 Queensland University Of Technology Skin regeneration system
US8586357B2 (en) * 2003-12-23 2013-11-19 Viacyte, Inc. Markers of definitive endoderm
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
US7625753B2 (en) * 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
CN103898047B (zh) * 2003-12-23 2020-03-03 维亚希特公司 定形内胚层
EP1767618A4 (en) * 2004-06-03 2008-07-30 Univ Kyoto INDUCTION OF AN INSULIN SEPARATING CELL
MX2007001772A (es) * 2004-08-13 2007-07-11 Univ Georgia Res Found Composiciones y metodos para auto-renovacion y diferenciacion de celulas troncales embrionicas humanas.
WO2006054305A2 (en) * 2004-11-22 2006-05-26 Ramot At Tel Aviv University Ltd. Populations of expanded and re-differentiated adult islet beta cells capable of producing insulin and methods of generating same
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
WO2006071802A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
JP5584875B2 (ja) * 2005-04-13 2014-09-10 国立大学法人 千葉大学 成体膵由来膵幹細胞の製造方法
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
DK1888123T3 (da) 2005-06-08 2013-04-15 Janssen Biotech Inc Celleterapi til øjendegeneration
US9487755B2 (en) * 2005-10-06 2016-11-08 David Moscatello Cell culture media, kits and methods of use
DK2674485T3 (da) 2005-10-27 2019-08-26 Viacyte Inc Pdx-1 udtrykkende dorsal og ventral fortarm endoderm
AU2006241302A1 (en) * 2005-11-18 2007-06-07 Lifescan, Inc. A method for creating cell clusters
WO2007070870A1 (en) 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
DK2650360T3 (da) * 2006-03-02 2019-10-07 Viacyte Inc Endokrine prekursorceller, pancreatiske hormon udtrykkende celler og fremgangsmåder til fremstilling
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
US20090286317A1 (en) * 2006-09-14 2009-11-19 Probiogen Ag Modular culture system for maintenance, differentiation and proliferation of cells
US20100323442A1 (en) * 2006-10-17 2010-12-23 Emmanuel Edward Baetge Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells
WO2008124169A2 (en) * 2007-04-10 2008-10-16 The Trustees Of The University Of Pennsylvania Islet cells composition and methods
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
RU2473685C2 (ru) 2007-07-31 2013-01-27 Лайфскен, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
CA2694956C (en) 2007-07-31 2017-12-19 Lifescan, Inc. Pluripotent stem cell differentiation by using human feeder cells
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US7846974B2 (en) * 2007-10-24 2010-12-07 National University Corporation Gunma University Method of lowering blood glucose and method of treating diabetes and obesity
KR20090051695A (ko) * 2007-11-19 2009-05-22 배용석 췌도 주변세포를 인슐린을 분비할 수 있는 세포로 분화시키는 방법
WO2009070592A2 (en) 2007-11-27 2009-06-04 Lifescan, Inc. Differentiation of human embryonic stem cells
BR122017025207B1 (pt) 2008-02-21 2021-03-16 Centocor Ortho Biotech Inc superfície que faz parte de um recipiente ou matriz destinada para uso em uma cultura de células ou análises, desprovida de uma camada de células alimentadoras e desprovida de uma camada adsorvente
US8728812B2 (en) * 2008-04-22 2014-05-20 President And Fellows Of Harvard College Compositions and methods for promoting the generation of PDX1+ pancreatic cells
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US7939322B2 (en) 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm
CA2729121C (en) 2008-06-30 2019-04-09 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
US8420592B2 (en) * 2008-08-30 2013-04-16 The Medicines Company Methods of treatment using single doses of oritavancin
JP5307489B2 (ja) * 2008-09-19 2013-10-02 株式会社クラレ 三次元細胞構造体の作製方法
RU2522001C2 (ru) 2008-10-31 2014-07-10 Сентокор Орто Байотек Инк. Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток
US9012218B2 (en) 2008-10-31 2015-04-21 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US8278106B2 (en) 2008-11-14 2012-10-02 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
KR101687344B1 (ko) 2008-11-20 2016-12-16 얀센 바이오테크 인코포레이티드 평면 기재상의 세포 부착 및 배양을 위한 방법 및 조성물
CN107267442A (zh) 2008-11-20 2017-10-20 詹森生物科技公司 微载体上的多能干细胞培养
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
EP2379088B1 (en) 2008-12-19 2018-02-28 DePuy Synthes Products, Inc. Treatment of lung and pulmonary diseases and disorders
IL196820A0 (en) 2009-02-01 2009-11-18 Yissum Res Dev Co Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells
JP5908394B2 (ja) 2009-03-26 2016-04-26 デピュイ・シンセス・プロダクツ・インコーポレイテッド アルツハイマー病の療法としてのヒト臍帯組織細胞
WO2010135639A2 (en) * 2009-05-21 2010-11-25 Joslin Diabetes Center, Inc. Compositions and methods for promoting beta cell maturity
KR20170118969A (ko) 2009-07-20 2017-10-25 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
KR101785626B1 (ko) 2009-07-20 2017-10-16 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
AU2010276402B2 (en) 2009-07-20 2014-07-03 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2010333840B2 (en) 2009-12-23 2016-01-07 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
BR112012017761A2 (pt) 2009-12-23 2015-09-15 Centocor Ortho Biotech Inc diferenciação das células-tronco embrionárias humanas
CN102791851B (zh) 2010-03-01 2017-07-14 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
JP6050225B2 (ja) 2010-05-12 2016-12-21 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
CN101880648B (zh) * 2010-06-25 2012-10-03 广东药学院 一种胰腺腺泡细胞的原代培养方法
ES2660897T3 (es) 2010-08-31 2018-03-26 Janssen Biotech, Inc. Diferenciación de células madre embrionarias humanas
EP2611910B1 (en) 2010-08-31 2018-01-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
ES2585028T3 (es) 2010-08-31 2016-10-03 Janssen Biotech, Inc. Diferenciación de células madre pluripotentes
EP2652125B1 (en) * 2010-12-15 2017-04-26 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
US20140242038A1 (en) * 2011-10-11 2014-08-28 The Trustees Of Columbia University In The City Of New York Method for generating beta cells
AU2012335070A1 (en) * 2011-11-11 2014-05-29 Bio-Ess Laboratories, Llc Kit comprising serum replacement and labile factors
SG11201403473QA (en) 2011-12-22 2014-10-30 Janssen Biotech Inc Differentiation of human embryonic stem cells into single hormonal insulin positive cells
JP6301263B2 (ja) 2011-12-23 2018-03-28 デピュイ・シンセス・プロダクツ・インコーポレイテッド ヒト臍帯組織由来細胞の検出
US9434920B2 (en) 2012-03-07 2016-09-06 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
KR102114209B1 (ko) 2012-06-08 2020-05-25 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화
US10344264B2 (en) 2012-12-31 2019-07-09 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
CA2896750A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
CN111394298A (zh) 2012-12-31 2020-07-10 詹森生物科技公司 使用hb9调节子使人胚胎干细胞分化为胰腺内分泌细胞的方法
US20170029778A1 (en) 2013-06-11 2017-02-02 President And Fellows Of Harvard College Sc-beta cells and compositions and methods for generating the same
CA2915143C (en) * 2013-06-13 2021-08-03 Orgenesis Ltd. Cell populations, methods of transdifferentiation and methods of use thereof
SG11201609473XA (en) 2014-05-16 2016-12-29 Janssen Biotech Inc Use of small molecules to enhance mafa expression in pancreatic endocrine cells
WO2016100930A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived b cells and methods of use thereof
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
CN104593399A (zh) * 2014-12-22 2015-05-06 广西大学 一种转基因胰岛素的合成工艺
MA41296A (fr) 2014-12-30 2017-11-07 Orgenesis Ltd Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
CN106680510B (zh) * 2016-12-27 2018-02-27 中南大学湘雅医院 Myoferlin及其特异性抗体在制备检测鼻咽癌试剂盒中的应用
AU2018215170B2 (en) * 2017-01-31 2021-11-11 Osaka University Differentiation control method for pluripotent stem cells
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2018207179A1 (en) 2017-05-08 2018-11-15 Orgenesis Ltd. Transdifferentiated cell populations and methods of use thereof
CN107034177B (zh) * 2017-06-02 2021-01-19 北京市农林科学院 一种牛卵泡膜细胞体外培养调节剂及其应用
WO2019073055A1 (en) 2017-10-13 2019-04-18 Imba - Institut Für Molekulare Biotechnologie Gmbh ENHANCED REPROGRAMMING OF SOMATIC CELLS
BR112020009275A2 (pt) 2017-11-15 2020-10-27 Semma Therapeutics, Inc. composições de fabricação de célula de ilhota e métodos de uso
AU2019320072A1 (en) 2018-08-10 2021-02-25 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112956453B (zh) * 2021-04-07 2022-10-11 华北理工大学 一种黑腹果蝇胰岛素抵抗糖尿病模型的建立方法
CN113341152B (zh) * 2021-04-27 2022-04-26 华南农业大学 Rps9蛋白在食蟹猴超数排卵良好应答预测中的应用
US11735303B2 (en) 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment
CN114250194B (zh) * 2021-11-30 2023-04-11 四川大学华西医院 一种急性胰腺炎细胞模型的构建方法和用途
WO2023123299A1 (en) * 2021-12-31 2023-07-06 Beijing Theraxyte Bioscience Co., Ltd. Compositions and methods for culturing stem cells
CN115282065B (zh) * 2022-08-11 2024-03-15 顾帅 一种含间充质干细胞外泌体的冻干粉及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332893A (en) * 1980-06-13 1982-06-01 Rosenberg Ralph A Process for the production of an insulin-producing cell line of pancreatic beta cells
DE3801236A1 (de) * 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
US5834308A (en) * 1994-04-28 1998-11-10 University Of Florida Research Foundation, Inc. In vitro growth of functional islets of Langerhans
US6001647A (en) * 1994-04-28 1999-12-14 Ixion Biotechnology, Inc. In vitro growth of functional islets of Langerhans and in vivo uses thereof
US6043092A (en) * 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US5935852A (en) * 1997-07-03 1999-08-10 Genetics Institute, Inc. DNA molecules encoding mammalian cerberus-like proteins
CA2339326A1 (en) * 1998-08-10 2000-02-24 Josephine Egan Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
EP1175487A2 (en) * 1999-02-10 2002-01-30 Curis, Inc. Pancreatic progenitor cells, methods and uses related thereto
US6946293B1 (en) * 1999-02-10 2005-09-20 Es Cell International Pte Ltd. Progenitor cells, methods and uses related thereto
US6362201B1 (en) * 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6967019B2 (en) * 1999-04-06 2005-11-22 The Regents Of The University Of California Production of pancreatic islet cells and delivery of insulin
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
WO2001032839A2 (en) * 1999-10-29 2001-05-10 Mcgill University Medium for preparing dedifferentiated cells
US6382201B1 (en) * 1999-11-17 2002-05-07 Mathew A. McPherson Bow vibration damper
US6610535B1 (en) * 2000-02-10 2003-08-26 Es Cell International Pte Ltd. Progenitor cells and methods and uses related thereto
JP2003523199A (ja) * 2000-02-18 2003-08-05 ザ ウォルター アンド イライザ ホール インスティチュート オブ メディカル リサーチ 膵島細胞成長因子
US6436704B1 (en) * 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
FR2814752A1 (fr) * 2000-10-02 2002-04-05 Chru Lille Procede d'obtention in vitro de cellules insulino- secretrices de mammifere et leurs utilisations
US6642003B2 (en) * 2001-08-02 2003-11-04 Cedars-Sinai Medical Center Human glucose-dependent insulin-secreting cell line
US7524492B2 (en) * 2001-08-31 2009-04-28 Joslin Diabetes Center, Inc. Insulin related transcription factor and uses thereof
CA2463914A1 (en) * 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells
US20060122104A1 (en) * 2002-05-28 2006-06-08 Presnell Sharon C Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells

Also Published As

Publication number Publication date
US20040127406A1 (en) 2004-07-01
EP1578925A2 (en) 2005-09-28
JP2006512046A (ja) 2006-04-13
US20040132183A1 (en) 2004-07-08
CA2485862A1 (en) 2003-12-11
AU2003273573A1 (en) 2003-12-19
BR0311413A (pt) 2005-03-22
CN1662643A (zh) 2005-08-31
WO2003102134A2 (en) 2003-12-11
CN1819838A (zh) 2006-08-16
WO2003100038A1 (en) 2003-12-04
WO2003102134A3 (en) 2005-12-01
WO2003102171A9 (en) 2005-01-20
CA2487094A1 (en) 2003-12-11
EP1507848A1 (en) 2005-02-23
EP1578925A4 (en) 2006-10-11
AU2003234666A1 (en) 2003-12-12
AU2003228255A1 (en) 2003-12-19
US20060275900A1 (en) 2006-12-07
US20060122104A1 (en) 2006-06-08
WO2003102171A1 (en) 2003-12-11
EP1507849A1 (en) 2005-02-23
US20040259244A1 (en) 2004-12-23
JP2005527241A (ja) 2005-09-15
EP1507849A4 (en) 2006-05-03
EP1507848A4 (en) 2005-11-23

Similar Documents

Publication Publication Date Title
BR0311360A (pt) métodos para expansão e transdiferenciação in vitro de células acinares pancreáticas humanas em células produtoras de insulina
DK1543106T3 (da) Fremgangsmåder og medier til kontrol af sialylering af proteiner, der dannes af mammaliaceller
WO2008060541A3 (en) In vitro expansion of postpartum-derived cells using microcarriers
BR0302172A (pt) Gama-proteobactéria, e, método para produzir uma substância alvo
BR9805900B1 (pt) processo para integrar um fragmento de dna no genoma de uma célula de uma planta manocotiledÈnea.
WO2007044418A3 (en) Cell culture media, kits and methods of use
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
BR0212780A (pt) Métodos para produzir polipeptìdeos em células eucarióticas, para cultivar células eucarióticas e para colher polipeptìdeos produzidos por células eucarióticas
WO2006127809A3 (en) Methods for expansion and analysis of cultured hematopoietic stem cells
BRPI0414789A (pt) microgéis em meios orgánicos reticuláveis
DK1526172T3 (da) Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira
DK1650307T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner ved anvendelse af apoptoseinhibitorer
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BR0012712A (pt) Métodos de produção de l-aminoácidos aumentando-se o nadph celular
PT980263E (pt) Produto de combinacao que associa um acido nucleico a uma substancia desorganizadora da matriz extracelular para terapia genetica
BR0316757A (pt) Composições de meio de cultura de célula, processo para a cultura de célula progenitoras e/ou tronco, processo para a produção de mioblastos, população de células, e uso de mioblastos
BR0206546A (pt) Método para a produção secretória de glicoproteìna que tem cadeia de açúcar do tipo humana, usando célula vegetal
BR9815440A (pt) Células intestinais parasitas viáveis isoladas
BR0203531A (pt) Método para produzir uma substáncia alvo pelo uso de um microorganismo, e, microorganismo no qual um gene da metanol desidrogenase é introduzido
DE602006014534D1 (de) Herstellung und verwendung von basalmembranpartikeln
BRPI0407002A (pt) Células cultivadas que apresentam antìgeno cd14+
BRPI0403200A (pt) Método para recrescimento de células embriogênicas crioconservadas de conìferas
AR023904A1 (es) Anticuerpos para el antigeno de las celulas dendriticas y sus usos
BR112022018640A2 (pt) Métodos para produzir uma população de células compreendendo cardiomiócitos e para purificar cardiomiócitos, população de células contendo cardiomiócitos, e, agente para terapia de transplante de células
BR9808554A (pt) Esterase do ácido fenólico e o uso da mesma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.

B15K Others concerning applications: alteration of classification

Ipc: C12N 5/071 (2010.01), C12N 5/00 (2006.01), A61K 35